Thank you, Amir. Good morning, everyone. Centrus reported another exceptional year of accomplishments exhibited by a year-over-year increase to revenue of nearly 40%. In addition, the company has undertaken several initiatives to improve its balance sheet and capital structure, including reducing the majority of our pension obligations, significant capital raises in the debt and equity markets, strengthening our cash position, SG&A optimization efforts yielding identifiable cost reductions, investment in our manufacturing capabilities to accelerate our time to deployment for our own plant production, and finally leveraging investment tax credit opportunities to partially fund these efforts In 2024, we generated $442 million in revenue, an increase of $121.8 million compared to 2023, and generated $73.2 million in net income compared to $84.4 million last year. We reported a gross profit of $111.5 million compared to $112.1 million in the prior year. Our LEU business generated $349.9 million in revenue, an increase of $80.9 million compared to 2023, driven by our growth in uranium and SWU revenue. The growth in SWU revenue was a result of a higher average price of SWU sold, partially offset by lower volume sold. The growth in uranium revenue was driven by increases in both the volume and average price of uranium sold. Furthermore, rising uranium commodity prices contributed largely to the year-over-year margin improvement by over 10%. Our cost of sales in LEU increased from $163.9 million in 2023 to $256 million in 2024, due to an increase in average SWU and uranium cost. SWU costs increased primarily as a result of a 67% increase in the average unit cost of SWU sold. Of the $256 million cost of sales, 25% is attributable to the release of costs related to previously deferred sales which incorporate the higher SWU price at the time of the deferral. Excluding the impact of these deferred sales deliveries, the average unit cost of SWUs sold would have only increased 27%. As I mentioned, the reason for the increase in uranium sales also drove similar increases in uranium costs. We ended the year with a gross profit of $93.9 million in our LEU segment compared to $105.1 million in 2023. Our Technical Solutions segment also generated $17.6 million in gross profit which was an improvement of $10.6 million over the prior year. As previously noted, on a consolidated basis, our gross profit was $111.5 million compared to a gross profit of $112.1 million in the prior year. Technical Solutions generated $92.1 million in revenue, an increase of $40.9 million compared to 2023, and reported $74.5 million in cost of sales, an increase of $30.3 million compared to the prior year. Our results on a year-over-year basis reflect the transition of the HALEU operation contract from Phase I, which was a cost-share arrangement to Phase II, which is a cost-plus-incentive fee arrangement. Our total company backlog was $3.7 billion as of year-end and extends to 2040. Our LEU segment backlog was approximately $2.8 billion and includes $0.8 billion of future SWU and uranium deliveries, primarily under medium- and long-term contracts with fixed commitments and $2 billion in contingent LEU sales commitments in support of potential construction of LEU production capacity at the Piketon, Ohio facility. During the first quarter, we entered into definitive agreements for $0.8 billion of the total $2 billion in contingent LEU sales commitments. The contingent LEU sales commitments continue to depend on our ability to secure substantial public and private investment. Our Technical Solutions segment backlog was approximately $0.9 billion and includes funded amounts, unfunded amounts and unexercised options. The unexercised options relate to the company's HALEU operation contract. As Amir noted, in the fourth quarter, we issued $402.5 million of 2.25% convertible senior notes for total net proceeds of $388.7 million. The proceeds from the offering deliver added liquidity to execute our strategic plans including our announcement for a $60 million investment for the resumption of centrifuge manufacturing activities and expansion of manufacturing capacity at our Oak Ridge, Tennessee facility that we announced in November 2024. We will also consider other strategic uses of these funds, including the possible retirement of our higher interest notes bearing 8.25% coupon, which have a principal value of $74.3 million. The issuance of the convertible notes follows the progress made in 2024 on further de-risking our balance sheet by reducing our pension plan obligations by approximately $280 million. As of the end of the year, we have $26 million remaining in these pension plan obligations with a funding level in excess of 118%. This will have ongoing savings realized through elimination of substantial recurring annual costs associated with the plants' administration, asset management fees, regulatory requirements, as well as the funding shortfall at the beginning of the year, for which the Company was ultimately responsible. Our continued positive operating results, coupled with the successful close of the convertible debt transaction and the reduction of our pension plan obligations contributed to an ending unrestricted cash balance of $671.4 million. Maintaining and growing a strong cash position continues to be a key in facilitating execution of our near-term contractual obligations as well as strategic investments in our long-term future. The Company is also engaged in exploring opportunities for investment tax credits. To this end, Centrus submitted an application in October 2024 for a clean energy manufacturing and recycling project credit. In January of '25, we received notification that we were approved for our request for $62.4 million in credit allocations for the manufacturing facility in Oak Ridge predicated on meeting certain requirements, including future investment in eligible property. All of the announced initiatives and investments are a part of a broad strategy to continue to optimize our cost structure, adequately manage our risks, and better position ourselves to execute on our vision to restore America's ability to enrich uranium at scale. With that, let me turn things back over to Amir.